UTHR Phase 2 — Tyvaso
2026-05-01
Phase 2 trial results for Tyvaso in idiopathic pulmonary fibrosis are due May 1, 2026. A clean hit validates the program; a miss can gap the stock down hard.

Primary source: https://www.sec.gov/Archives/edgar/data/1082554/000110465926036445/tm2610558d1_ex99-1.htm

Track it: https://www.pharmaconomics.com/e/913
